Alumis (ALMS) tumbles on Phase 2b LUMUS endpoint miss
Alumis Inc. shares plunged about 57% after Phase 2b LUMUS missed overall primary and key secondary endpoints, though the high–interferon subgroup met them. HC Wainwright upgraded and cut its target to $15; Wells Fargo cut to $25.